Business Context and Reporting Period
This Form 6-K, dated November 24, 2019, reports on a strategic acquisition by Novartis AG. The filing announces an agreement to acquire The Medicines Company, a US-based biopharmaceutical firm, to add the investigational cholesterol-lowering therapy inclisiran to Novartis's portfolio. The transaction aligns with Novartis's strategy to transform into a focused medicines company and address atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH).
Key Financial Metrics and Transaction Details
- Acquisition Value: Approximately USD 9.7 billion on a fully diluted equity basis.
- Offer Price: USD 85.00 per share in cash.
- Premium: Approximately 41% over The Medicines Company's 30-day volume-weighted average price (USD 60.33) and 24% over the closing share price on November 22, 2019 (USD 68.55).
- Financing: Planned through available cash and short- and long-term borrowings.
- Revenue Impact: Inclisiran is expected to contribute to Group and Innovative Medicines (IM) Division sales starting in 2021.
- Margin Outlook: Novartis updated its IM Division core margin outlook to mid-thirties in the near term and mid-to-high thirties in the medium term.
Material Changes and Strategic Outlook
The primary material change is the entry into a merger agreement to acquire The Medicines Company. This transaction is expected to modestly dilute core earnings per share (EPS) in the near term due to launch investments but is projected to be significantly accretive to Group core operating income and core EPS in the medium term. The acquisition leverages Novartis's existing global cardiovascular commercial capabilities to drive growth in the Cardiovascular-Renal-Metabolism franchise.
Guidance, Risks, and Contingencies
- Regulatory Timeline: The Medicines Company expects to file regulatory submissions in the U.S. in Q4 2019 and in Europe in Q1 2020. An ongoing Phase III trial (ORION-4) is evaluating cardiovascular morbidity and mortality benefits.
- Closing Conditions: The transaction is expected to close in Q1 2020, subject to customary conditions including antitrust clearance and regulatory approvals.
- Margin Assumptions: The updated margin guidance assumes no Gilenya generics will enter the U.S. market in 2020.
- Risks: Risks include potential regulatory delays, failure to realize synergies, integration challenges, and the uncertainty of clinical trial outcomes and commercialization success for inclisiran.
Key Facts for Investor Verification
- Confirmation of the final closing date and satisfaction of antitrust clearance conditions.
- Actual regulatory filing dates and approval status for inclisiran in the U.S. and Europe.
- Impact of the acquisition on Novartis's debt levels and liquidity ratios post-closing.
- Progress of the ORION-4 clinical trial regarding cardiovascular outcomes.
- Verification of the assumption regarding Gilenya generic entry in the U.S. market for 2020.